While very low-count MBL not often progresses to CLL, higher-rely MBL progresses to CLL requiring therapy at a rate of 1% to 2% annually. Large-count MBL is distinguished from Rai 0 CLL based on whether or not the B-mobile rely is above or below 5 × 109/L. Despite the fact that individuals with both high-count MBL and CLL Rai stage 0 are at elevat